RecruitingPhase 2NCT05043116

High-dose Vitamin D Supplement for the Prevention of Acute Asthma-like Symptoms in Preschool Children

High-dose Vitamin D Supplement for the Prevention of Acute Asthma-like Symptoms in Preschool Children - a Double-blind, Randomized, Controlled Trial


Sponsor

Copenhagen Studies on Asthma in Childhood

Enrollment

320 participants

Start Date

Oct 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

To investigate whether high-dose vitamin D supplementation may have a beneficial effect on secondary prevention in preschool children (1-5 years of age), with respiratory infections being the primary cause of acute exacerbations with asthma-like symptoms.


Eligibility

Min Age: 12 MonthsMax Age: 71 Months

Inclusion Criteria1

  • The study population consists of children in the age group 1-5 years admitted to a pediatric ward, due to an acute episode with asthma-like symptoms. An acute asthma-like episode will be defined as annoying coughing, wheezing (wheezing or wheezing in connection with exhalation) and / or dyspnoea, which affects the child's well-being and requires hospitalization in a pediatric ward. Participation in the study requires that the child is in or has been in treatment with SABA, as monotherapy, or in combination with ICS, and possibly also in combination with LTRA in accordance with the Danish guidelines

Exclusion Criteria11

  • The child is hospitalized with pneumonia
  • The child's daily intake of vitamin D supplementation is\> 400 IU / day (\~ 10 μg / day).
  • The child is given a combination of vitamin and dietary supplements containing vitamin D, thus the daily recommended dose is exceeded, as 2400 IU / day (\~ 60 μg / day) is accepted for children aged 1-4 years, as everyone here is recommended to take 400 IU / day (\~ 10 μg / day) by the Danish Health and Medicines Authority.
  • The baby has been exclusively breastfed for the past 6 months.
  • The child is malnourished
  • for children\> 2 years of age whose age-specific BMI is less than the 3rd percentile.
  • for children \<2 years, whose weight or height in relation to age is less than the 3rd percentile.
  • The child is a newly arrived refugee or immigrant from regions with a high risk of rickets.
  • The child has other chronic lung diseases.
  • The child is diagnosed with other conditions such as chronic lung disease, impaired renal function, neurological or psychiatric disorders, congenital or documented acquired QT prolongation, clinically relevant bradycardia, cardiac arrhythmia or severe heart failure and / or hepatic impairment.
  • The child is being treated with medication that alters calcium or vitamin D absorption / metabolism.

Interventions

DIETARY_SUPPLEMENTCholecalciferol D3

2000 IU of Vitamin D provided as oral suspension for one year

OTHEROral placebo suspension

Oral suspension with no active substance tasting like the active supplement.


Locations(1)

University Hospital of Copenhagen

Gentofte Municipality, Gentofte, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05043116


Related Trials